alfacalcidol + hydrochlorothiazide + amiloride

This combination therapy regimen, investigated by Assistance Publique - Hôpitaux de Paris, consists of alfacalcidol, hydrochlorothiazide, and amiloride. It is specifically designed for the management of severe primary hypoparathyroidism and autosomal dominant hypocalcemia. Alfacalcidol, an activated vitamin D analogue, addresses hypocalcemia by promoting intestinal calcium absorption. Hydrochlorothiazide, a thiazide diuretic, is included to reduce hypercalciuria by increasing renal calcium reabsorption, thereby lowering the risk of nephrocalcinosis and renal impairment. Amiloride, a potassium-sparing diuretic, is added to the regimen to counteract the hypokalemia typically induced by thiazide diuretics. This triple-therapy approach is being evaluated as an alternative to parathyroid hormone replacement therapy (such as teriparatide) to maintain stable calcium homeostasis while protecting renal function.

Brand names

Modamide

Other names

Alfacalcidol/Hydrochlorothiazide/AmilorideAlfacalcidol + Hydrochlorothiazide + Amiloride